弗拉克斯医疗保健有限公司美股招股说明书(2025-09-26版)

We are offering 60,000,000 shares of our common stock, par value $0.00001 per share. Our common stock is listed on The Nasdaq Global Market under the symbol “GUTS.” The last reported sale price of our common stock on TheNasdaq Global Market on September25, 2025 was $1.01 per share. Investing in our securities involves a high degree of risk. See “Risk Factors” beginning on pageS-7of thisprospectus supplement, page 8 of the accompanying prospectus and under similar headings in the documentsincorporated by reference into this prospectus supplement and the accompanying prospectus. We are an “emerging growth company” and a “smaller reporting company” under applicable Securities and Exchange Commission rules and aresubject to reduced public company reporting requirements. See “Prospectus Supplement Summary—Implications of Being an Emerging GrowthCompany and a Smaller Reporting Company.” Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities ordetermined ifthisprospectus supplement or the accompanying prospectus is truthful or complete. Any representation to the contrary is acriminal offense. (1)We refer you to “Underwriting” beginning on pageS-19of this prospectus supplement for additional information regarding underwritingcompensation. Delivery of the shares of our common stock is expected to be made on or about September29, 2025. Evercore ISI BofA Securities Ladenburg Thalmann Prospectus Supplement dated September26, 2025 Table of Contents TABLE OF CONTENTS PROSPECTUS SUPPLEMENT ABOUT THIS PROSPECTUS SUPPLEMENTSPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTSPROSPECTUS SUPPLEMENT SUMMARYRISK FACTORSUSE OF PROCEEDSDIVIDEND POLICYCAPITALIZATIONDILUTIONMATERIAL U.S. FEDERAL INCOME TAX CONSIDERATIONS TONON-U.S.HOLDERSUNDERWRITINGLEGAL MATTERSEXPERTSWHERE YOU CAN FIND MORE INFORMATIONINCORPORATION OF CERTAIN INFORMATION BY REFERENCE PROSPECTUS ABOUT THIS PROSPECTUSSPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTSWHERE YOU CAN FIND MORE INFORMATION; INCORPORATION BY REFERENCETHE COMPANYRISK FACTORSUSE OF PROCEEDSDESCRIPTION OF CAPITAL STOCKDESCRIPTION OF DEBT SECURITIESDESCRIPTION OF WARRANTSGLOBAL SECURITIESPLAN OF DISTRIBUTIONLEGAL MATTERSEXPERTS Table of Contents ABOUT THIS PROSPECTUS SUPPLEMENT This prospectus supplement is part of a “shelf” registration statement on FormS-3(FileNo.333-285522)that we filed with the Securities andExchange Commission, or the SEC, and is in two parts. The first part is this prospectus supplement, which describes the specific terms of this offeringand also adds to and updates information contained in the accompanying prospectus and the documents incorporated by reference herein. The secondpart, the accompanying prospectus, provides more general information. Generally, when we refer to this prospectus, we are referring to both parts of thisdocument combined. To the extent there is a conflict between the information contained in this prospectus supplement and the information contained inthe accompanying prospectus or any document incorporated by reference therein filed prior to the date of this prospectus supplement, you should rely onthe information in this prospectus supplement; provided that if any statement in one of these documents is inconsistent with a statement in anotherdocument having a later date – for example, a document incorporated by reference in the accompanying prospectus – the statement in the documenthaving the later date modifies or supersedes the earlier statement. The information included or incorporated by reference in this prospectus supplementalso adds to, updates and changes information contained or incorporated by reference in the accompanying prospectus. Before buying any of the shares of common stock offered hereby, we urge you to read carefully this prospectus supplement and the accompanyingprospectus, together with the information incorporated herein by reference as described below under the heading “Incorporation of Certain Informationby Reference.” These documents contain important information that you should consider when making your investment decision. We further note thatthe representations, warranties and covenants made by us in any agreement that is filed as an exhibit to any document that is incorporated by referenceherein were made solely for the benefit of the parties to such agreement, including, in some cases, for the purpose of allocating risk among the parties tosuch agreements, and should not be deemed to be a representation, warranty or covenant to you. Moreover, such representations, warranties orcovenants were accurate only as of the date when made. Accordingly, such representations, warranties and covenants should not be relied on asaccurately representing the current state of our affairs. We have not authorized anyone to provide any information other than that contained or incorporated by reference in this prospectus supplement,the accompa